New Alzheimer’s Drug Shows Positive Results but Side Effects
Researchers released new details from a study of a closely watched drug for Alzheimer’s disease on Tuesday, shedding more light on the drug’s risks and benefits as U.S. health regulators weigh approving it. Eisai Co. and Biogen Inc.’s drug, called lecanemab, slowed cognitive decline by 27%…
#closelywatched #weighapproving #biogenincs #alzheimer #earlystagealzheimer #watcheddrug #eagleoutfitters #incsdrug #promocode #drug